DadFinStart your free week
DadFin › Stocks › Healthcare › CRON

Cronos Group Inc. (CRON) stock score

Healthcare · Drug Manufacturers - Specialty & Generic · Canada

$3.23 ▲ +0.31% today

41.4
Dad Score, out of 100
middling

Cronos Group Inc. (CRON) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, listed in Canada. On DadFin's weekly run it scores 41.4 out of 100 on the Dad Score, a middling reading that places the business ahead of 41% of the 5,774 US and Canadian stocks DadFin fully scores. Inside Healthcare it ranks #513 of 974. Its strongest axes are quality and growth; its weakest are valuation and risk.

Scores from the run of Oct 4, 2026. The Dad Score answers one question: how good is this business, measured against its own sector. How it is built →

The eight axes

Valuation
Weak
Quality
Above average
Growth
Strong
Price action
Average
Risk
Below average
Conviction
Average
Liquidity
Below average
Macro
Average

Each axis is ranked inside the stock's own sector. Subscribers see the percentile and every input behind each bar.

Key numbers

P/E (trailing)17.0×
P/E (forward)-80.6×
Dividend yield0.00%
Return on capital-2.1%
Operating margin15.4%
Revenue growth (YoY)+24.6%
FCF yield-0.0%
Net debt / EBITDA-66.99×
Piotroski F-Score5 / 9
52-week change+26.5%
Market cap$1.2B
Next earnings—

What subscribers see on CRON

Start your free weekSubscriber? Open the full research →

Drug Manufacturers - Specialty & Generic peers

StockCompanyDad ScoreBandMarket cap
TAKTakeda Pharmaceutical Company Limi32.9weak$57.1B
TEVATeva Pharmaceutical Industries Lim93.6strong$46.1B
HLNHaleon plc64.5middling$38.7B
ZTSZoetis Inc.61.2middling$28.8B
UTHRUnited Therapeutics Corporation99.8strong$23.2B
VTRSViatris Inc.54.4middling$20.2B
NBIXNeurocrine Biosciences, Inc.98.4strong$14.6B
ELANElanco Animal Health Incorporated84.0good$11.1B

Prices from DadFin's live feed (refreshed about every 15 minutes in the session); scores from the weekly run of Oct 4, 2026. Fundamentals as reported in the latest filings. Research, not investment advice.